A regenerative approach to the treatment of multiple sclerosis

Nature

Volumn 502, Issue 7471, 2013, Pages 327-332

  Deshmukh, Vishal A ^a   Tardif, Virginie ^b   Lyssiotis, Costas A ^a,b   Green, Chelsea C ^a   Kerman, Bilal ^c   Kim, Hyung Joon ^c   Padmanabhan, Krishnan ^c   Swoboda, Jonathan G ^a   Ahmad, Insha ^a   Kondo, Toru ^d   Gage, Fred H ^c   Theofilopoulos, Argyrios N ^b   Lawson, Brian R ^b   Schultz, Peter G ^a,e   Lairson, Luke L ^a,e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d HOKKAIDO UNIVERSITY   (Japan)

^e California Institute for Biomedical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BETA INTERFERON; CUPRIZONE; FINGOLIMOD; MUSCARINIC RECEPTOR; MYELIN BASIC PROTEIN;

BRAIN; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG; ENCEPHALITIS; IMMUNE RESPONSE; INHIBITION; PROTEIN;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGENERATIVE MEDICINE; REMYELINIZATION;

ANIMALS; ANTIPARKINSON AGENTS; BENZTROPINE; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; CUPRIZONE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNE SYSTEM; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; OLIGODENDROGLIA; OPTIC NERVE; PROPYLENE GLYCOLS; RATS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M3; RECURRENCE; REGENERATION; SPHINGOSINE; STEM CELLS;

RATTUS;

EID: 84885846072     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12647     Document Type: Article

References (54)

1. Franklin, R. J. & Ffrench-Constant, C. Remyelination in the CNS: from biology to therapy. Nature Rev. Neurosci. 9, 839-855 (2008).
2. Franklin, R. J. Why does remyelination fail in multiple sclerosis? Nature Rev. Neurosci. 3, 705-714 (2002).
3. Nunes, M. C. et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nature Med. 9, 439-447 (2003).
4. Belachew, S. et al. Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. J. Cell Biol. 161, 169-186 (2003).
5. Huang, J. K. et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nature Neurosci. 14, 45-53 (2011).
6. Gensert, J. M. & Goldman, J. E. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 19, 197-203 (1997).
7. Horner, P. J. et al. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J. Neurosci. 20, 2218-2228 (2000).
8. Kremer, D., Aktas, O., Hartung, H. P. & Kury, P. The complex world of oligodendroglial differentiation inhibitors. Ann. Neurol. 69, 602-618 (2011).
9. Patel, J. R. & Klein, R. S. Mediators of oligodendrocyte differentiation during remyelination. FEBS Lett. 585, 3730-3737 (2011).
10. Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346, 165-173 (2002).
11. Chari, D. M., Huang, W. L. & Blakemore, W. F. Dysfunctional oligodendrocyte progenitor cell (OPC) populations may inhibit repopulation of OPC depleted tissue. J. Neurosci. Res. 73, 787-793 (2003).
12. Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 18, 601-609 (1998).
13. Kuhlmann, T. et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131, 1749-1758 (2008).
14. Hart, I. K., Richardson, W. D., Bolsover, S. R. & Raff, M. C. PDGF and intracellular signaling in the timing of oligodendrocyte differentiation. J. Cell Biol. 109, 3411-3417 (1989).
15. Billon, N., Tokumoto, Y., Forrest, D. & Raff, M. Role of thyroid hormone receptors in timing oligodendrocyte differentiation. Dev. Biol. 235, 110-120 (2001).
16. Tokumoto, Y. M., Tang, D. G. & Raff, M. C. Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein. EMBO J. 20, 5261-5268 (2001).
17. Fernandez, M. et al. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc. Natl Acad. Sci. USA 101, 16363-16368 (2004).
18. Calzà, L., Fernandez, M. & Giardino, L. Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells. J. Mol. Endocrinol. 44, 13-23 (2010).
19. Barres, B. A., Lazar, M. A. & Raff, M. C. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 120, 1097-1108 (1994).
20. Buckley, C. E. et al. Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects. Neuropharmacology 59, 149-159 (2010).
21. Ibanez, C. et al. Steroids and the reversal of age-associated changes inmyelination and remyelination. Prog. Neurobiol. 71, 49-56 (2003).
22. Baer, A. S. et al. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcomeby pharmacologicalmodulation of Fyn-RhoA and protein kinase C signalling. Brain 132, 465-481 (2009).
23. Joubert, L. et al.Chemical inducers and transcriptionalmarkers of oligodendrocyte differentiation. J. Neurosci. Res. 88, 2546-2557 (2010).
24. Gard, A. L. & Pfeiffer, S. E. Two proliferative stages of the oligodendrocyte lineage (A2B51O42 and O41GalC2) under different mitogenic control. Neuron 5, 615-625 (1990).
25. Pfeiffer, S. E., Warrington, A. E. & Bansal, R. The oligodendrocyte and its many cellular processes. Trends Cell Biol. 3, 191-197 (1993).
26. Gaspard, N. et al. Generationof corticalneurons frommouse embryonic stemcells. Nature Protocols 4, 1454-1463 (2009).
27. Barres, B. A. et al. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70, 31-46 (1992).
28. Eshleman, A. J., Henningsen, R. A., Neve, K. A. & Janowsky, A. Release of dopamine via the human transporter. Mol. Pharmacol. 45, 312-316 (1994).
29. McKearney, J. W. Stimulant actions of histamine H1 antagonists on operant behavior in the squirrel monkey. Psychopharmacol. 77, 156-158 (1982).
30. Agoston, G. E. et al. Novel N-substituted 3a-[bis(4'-fluorophenyl) methoxy]tropane analogues: selective ligands for the dopamine transporter. J. Med. Chem. 40, 4329-4339 (1997).
31. De Angelis, F., Bernardo, A., Magnaghi, V., Minghetti, L. & Tata, A. M. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation and differentiation. Dev. Neurobiol. 72, 713-728 (2012).
32. Stidworthy, M. F. et al. Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 127, 1928-1941 (2004).
33. Taveggia, C., Feltri, M. L. & Wrabetz, L. Signals to promote myelin formation and repair. Nature Rev. Neurol. 6, 276-287 (2010).
34. Ragheb, F. et al. Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes. J. Neurochem. 77, 1396-1406 (2001).
35. Felder, C. C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J. 9, 619-625 (1995).
36. Owens, T. & Sriram, S. The immunology ofmultiple sclerosis and its animalmodel, experimental allergic encephalomyelitis. Neurol. Clin. 13, 51-73 (1995).
37. Lawson, B. R. et al. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J. Immunol. 178, 5366-5374 (2007).
38. Mix, E.,Meyer-Rienecker, H. & Zettl, U. K.Animalmodels ofmultiple sclerosis for the development and validation of novel therapies-potential and limitations. J. Neurol. 255 (Suppl 6), 7-14 (2008).
39. Steinman, L. & Zamvil, S. S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26, 565-571 (2005).
40. Aharoni, R. et al. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J. Autoimmun. 37, 228-241 (2011).
41. Liu, L. et al. Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J. Neurosci. 30, 9074-9083 (2010).
42. Mi, S. et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nature Med. 13, 1228-1233 (2007).
43. Kawashima, K. & Fujii, T. Basic and clinical aspects of non-neuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance. J. Pharmacol. Sci. 106, 167-173 (2008).
44. Stern, J. N. et al. Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc. Natl Acad. Sci. USA 107, 17280-17285 (2010).
45. Steelman, A. J., Thompson, J. P. & Li, J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci. Res. 72, 32-42 (2012).
46. Matsushima, G. K. & Morell, P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 11, 107-116 (2001).
47. Kappos, L. et al. Oral fingolimod (FTY720) for relapsingmultiple sclerosis. N. Engl. J. Med. 355, 1124-1140 (2006).
48. Durelli, L. et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359, 1453-1460 (2002).
49. Noronha, A., Toscas, A. & Jensen, M. A. Interferon b decreases T cell activation and interferon c production in multiple sclerosis. J. Neuroimmunol. 46, 145-153 (1993).
50. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457 (2002).
51. Kondo, T. & Raff, M. The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J. 19, 1998-2007 (2000).
52. Wang, S., Sdrulla, A., Johnson, J. E., Yokota, Y. & Barres, B. A. A role for the helixloop- helix protein Id2 in the control of oligodendrocyte development. Neuron 29, 603-614 (2001).
53. Pang, Y. et al. Neuron-oligodendrocyte myelination co-culture derived from embryonic rat spinal cord and cerebral cortex. Brain Behav. 2, 53-67 (2012).
54. Izrael, M. et al. Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol. Cell. Neurosci. 34, 310-323 (2007).